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The vaccinia virus A35R gene is highly conserved among poxviruses and encodes a previously uncharacter-
ized hydrophobic acidic protein. Western blotting with anti-A35R peptide antibodies indicated that the protein
is expressed early in infection and resolved as a single sharp band of 23 kDa, slightly higher than the 20 kDa
predicted from its sequence. The protein band appeared to be the same molecular weight on sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, whether expressed in an in vitro transcription/translation system
without microsomes or expressed in infected cells, suggesting that it was not glycosylated. A mutant virus with
the A35R gene deleted (vA35) formed wild-type-sized plaques on all cell lines tested (human, monkey, mouse,
and rabbit); thus, A35R is not required for replication and does not appear to be a host range gene. Although
the A35R protein is hydrophobic, it is unlikely to be an integral membrane protein, as it partitioned to the
aqueous phase during TX-114 partitioning. The protein could not be detected in virus-infected cell superna-
tants. A35R localized intracellularly to the virus factories, where the first stages of morphogenesis occur. The
vA35 mutant formed near-normal levels of the various morphogenic stages of infectious virus particles and
supported normal acid-induced fusion of virus-infected cells. Despite normal growth and morphogenesis in
vitro, the vA35 mutant virus was attenuated in intranasal challenge of mice compared to wild-type and A35R
rescue virus. Thus, the intracellular A35R protein plays a role in virulence. The A35R has little homology to
any protein outside of poxviruses, suggesting a novel virulence mechanism.
Poxviruses are large double-stranded DNA viruses with ge-
nomes that range from 130 to 379 kbp (39). Poxviruses have
worldwide distribution and infect a wide variety of animals,
including insects, birds, and mammals (18). While smallpox
was eradicated from nature, variola virus continues to present
a bioterrorism concern, and several other poxviruses infect
humans, causing morbidity and mortality: molluscum contagio-
sum virus (MCV), monkeypox virus, Tanapox virus, Yaba-like
disease virus, cowpox virus, and Cantagalo virus (evolved from
a vaccinia virus [VV] vaccine strain) (5, 7, 10, 16–18, 27, 32, 33,
38). The prevalence of poxviruses in animals and humans and
their propensity for recombination and gene acquisition sug-
gest that it would be unwise to discount them as important
human pathogens. This is especially true, since most emerging
infectious diseases are zoonoses, crossing from animals to hu-
mans, and poxviruses are known to acquire mutations and
become highly pathogenic in a new animal species (19).
The complex poxvirus replication cycle occurs in the cyto-
plasmic areas of dense viroplasm called virus factories. Gene
expression is temporally regulated, with early, intermediate,
and late gene expression. Early genes include those encoding
intermediate transcription factors, components of the DNA
replication machinery, inhibitors of cellular apoptosis and pro-
teins that interfere with immune clearance of virus-infected
cells. Among the last group, there are inhibitors of comple-
ment; alpha interferon (IFN-), IFN-, and IFN-; major his-
tocompatility complex class I expression; antigen presentation;
interleukin 1-converting enzyme; Fas-induced killing; chemo-
kines; and interleukins, (2, 34, 40, 54). While a great many viral
pathogenic strategies have been described, my colleagues and
I have documented that of the 90 most widely conserved pox-
virus genes, 25 remain uncharacterized (55). This fact under-
scores the large amount that is still unknown about poxviruses
and highlights the need for further study of these viruses and
genes.
Most poxvirus research has focused on VV, the prototypical
poxvirus that was used as the live smallpox vaccine (39). Pox-
virus morphogenesis is complex with multiple viral forms. The
spherical immature virus particle matures into the intracellular
mature virus (IMV) concomitant with proteolytic cleavage.
The IMV is infectious, but to escape the cell during infection,
IMV must undergo a second membrane-wrapping event, dur-
ing which the IMV acquires two additional membrane layers
derived from the trans-Golgi network or early endosomes,
forming the intracellular enveloped virus (IEV) (23, 28, 39,
48). The IEV fuses out, losing its outermost membrane and
releasing the extracellular enveloped virus (EEV) (6, 20, 26,
47, 56, 57, 59, 60). Seven proteins have been identified that are
specifically incorporated into the IEV and/or EEV mem-
branes: an 89-kDa hemagglutinin (encoded by the VV A56R
gene) (44, 53), a 42 kDa protein (B5R) (14, 15, 30), a 43- to
50-kDa protein (A36R) (43), the 65-kDa (F12L) protein (56,
61), the acylated 37-kDa (F13L) protein (3, 24), and two vari-
ably glycosylated 21- to 24-kDa proteins encoded by A33R and
A34R (11, 37, 46, 47). The A33R, A34R, and A36R envelope
genes are contained within a small contiguous region of the
genome interrupted only by the A35R open reading frame
(ORF). The location of the A35R and its hydrophobic nature
suggested that it might also be an envelope-associated protein.
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This report describes the first characterization of the A35R
protein and its role in virulence.
MATERIALS AND METHODS
Cells. HeLa cells were used for growth of virus stocks as previously described
(12). BS-C-1 cells were routinely used for plaque assays, immunostaining, im-
munoprecipitations, and Western blotting. For titrations of VV and analysis of
plaque size, monolayers were fixed and stained with 0.1% crystal violet in 20%
ethanol.
RK13 cells were used to propagate virus for CsCl purification of virus particles.
Cells were grown in Eagle’s minimum essential medium with 10% fetal bovine
serum, and infections were carried out in Eagle’s minimum essential medium
with 2.5% fetal bovine serum. Cell lines used for host range studies are listed
with the American Type Culture Collection number in parenthesis: RK-13,
normal rabbit kidney (CCL-37); CV-1, normal African Green monkey kidney
(CCL-70); HeLa, human cervical adenocarcinoma (CCL-2); human, thymidine
kinase-negative (TK) (CRL-8303); African green monkey normal kidney, BS-
C-1 (CCL-26); human lung carcinoma, A549 (CCL-185); normal human lung
fibroblast, MRC-5 (CCL-171); and hamster kidney, BHK-21 (CRL 8544).
Antibodies. Polyclonal rabbit sera were raised to three A35R peptides (sup-
plied by J. Coligan, National Institute of Allergy and Infectious Diseases). Se-
quences were derived from hydrophilic regions of the predicted amino acid
sequence of A35R. The peptide A35R-55 sequence was CQKCYFSYKGKIVP
QDSND (residues 55 to 72), the A35R-102 peptide sequence was CDIEDKH
QPFY (residues 102 to 111), and A35R-85 was YRSKNTIIIACDYDC (85 to
98). Cysteine residues (underlined) were included to aid in peptide coupling.
Peptides were coupled to keyhole limpet hemocyanin using the Imject Activated
Immunogen Conjugation kit (Pierce, Rockford, IL). A total of five injections
were given, and the rabbits were bled to prepare antiserum.
Cloning and in vitro expression of A35R. The Sal L opp plasmid (a gift from
Nelson Cole) was cut with NcoI and SpeI restriction enzymes to release a DNA
segment containing the A35R gene, from 1 nucleotide before the ATG transla-
tion start site to 37 nucleotides after the stop codon. The A35R segment and
NcoI- and SpeI-cut pGem5Zf (Promega) and pTM1 (39) plasmids were gel
purified using the Geneclean II kit, ligated, and transformed into Escherichia
coli. Ampicillin-resistant colonies were picked and screened for inserts. In vitro
expression was carried out using the TNT reticulolysate system (Promega) in the
absence of microsomal membranes.
vA35R mutant virus construction. DNA segments containing the A35R
flanking regions were joined with the E. coli xanthine guanine phosphoribosyl
transferase (gpt) gene under the p7.5 promoter by recombinant PCR (47, 58).
The flanking sequence that included part of the adjacent A34R gene was am-
plified by using the primer pair CCAGATTGCCTAGACCGGATACTAG and
GCGGGTGGGTTTGGAATTAGTGTGGCGGCGTACGTTAACGACTTA.
Sequences of the gpt gene (underlined) were incorporated into the primers for
sequential amplification and joining of the gpt and A35R flanking regions. The
flanking sequence that included part of the adjacent A36R gene was amplified
using the primer pair CCTGGCACTGCCGGGCGTTCATAAAAGTTGTAA
AGTAAATAATAAAAC and TCATTCCTAGAAATATTATCTACG. Primers
used to amplify the gpt cassette were CACTAATTCCAAACCCACCCGCTT
and AACGCCCGGCAGTGCCAGGCGT. The three DNA segments were am-
plified by PCR individually, purified by using Promega PCR Preps, and then
joined by recombinant PCR in a stepwise fashion. The final PCR product was
purified, TA cloned (Invitrogen), and sequenced using a Prism Dye Deoxy
Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, Calif.) in
conjunction with a model 373 DNA sequencer (Applied Biosystems). The TA
plasmid containing the A35 construct was transfected with N-[1-(2,3-dioleoy-
loxy)propyl]-N,N,N-trimethylammonium methyl-sulfate (DOTAP; Roche) into
cells infected with the wild-type VV strain Western Reserve (WR). Viruses were
grown under semisolid agarose (GIBCO/BRL, Grand Island, N.Y.) containing
mycophenolic acid (Sigma) for selection of recombinant virus. Viruses were
plaque purified three times and amplified. Recombinant viruses were PCR
screened for the presence of the gpt gene and the absence of the A35R gene
using primers flanking the A35R locus. Protein expression was analyzed by
Western blotting.
vA35-Res virus construction. The A35R gene and flanking sequences were
PCR amplified using primers CCAGATTGCCTAGACCGGATACTAG and
TCATTCCTAGAAATATTATCTACG. The PCR product was cloned into the
TA cloning vector (Invitrogen). Plasmids were sequenced to confirm the correct
sequence and transfected into vA35-infected cells. vA35-Res recombinant vi-
ruses were selected on STO cells in the presence of 6-thioguanine to select
against viruses containing the gpt gene (29). Expression of A35R protein was
confirmed by Western blotting.
Immunoprecipitation and Western blotting. Immunoprecipitation and West-
ern blots were performed essentially as described previously (46). Rabbit anti-
A35R sera were used at a 1:1,000 dilution in Western blots.
Triton X-114 partitioning of integral membrane proteins. BS-C-1 cells were
infected at a multiplicity of infection (MOI) of 10 for 24 h. The medium was
removed, and cells were extracted in cold buffer containing 10 mM Tris-HCl (pH
7.4), 150 mM NaCl, and 2% Triton X-114 (Pierce, Rockford, IL). Following a
15-min incubation, lysates were centrifuged for 7 min at 14,000  g to remove
insoluble matter. Supernatants were warmed to 37°C, underlaid twice with 6%
sucrose, and centrifuged for 10 min at 1,000  g to separate the upper aqueous
phase from the lower detergent phase. Samples were analyzed by immunopre-
cipitation and sodium dodecyl sulfate-polyacrylamide gel electrophoresis.
Immunofluorescence microscopy. Fluorescence microscopy was performed as
previously described (47). Infected HeLa cell monolayers on coverslips were
washed with phosphate-buffered saline (PBS), fixed in 4% paraformaldehyde,
and permeabilized with 0.1% Triton X-100. Rabbit anti-A35R sera were used at
a 1:1,000 dilution. The secondary antibody was Alexa 568-labeled goat anti-rabbit
immunoglobulin G (Molecular Probes, Inc.) diluted 1:400, and DNA was stained
by 500-ng/ml Hoechst 33258 (Sigma). Samples were viewed and images were
collected with a Zeiss IIIRS immunofluorescent microscope.
One-step growth curve. Confluent BS-C-1 cell monolayers in six-well plates
were infected with VV at an MOI of 10 for 2 h. The inocula were removed, the
cells were washed, and fresh medium was added. At intervals, the medium from
an individual well was harvested and centrifuged at 1,800  g for 5 min to pellet
detached cells. The resulting cell pellet was combined with infected cells that had
been scraped from the plate into 1 ml of fresh medium. Cells were frozen, thawed
three times, and sonicated. Viruses from the media and cells were individually
titrated in duplicate on BS-C-1 cell monolayers.
Virus purification. Virus particles were separated and purified based on dif-
ferential buoyant density centrifugation in CsCl, as described previously (46).
Briefly, RK-13 cells were infected at a multiplicity of infection of 10 for 48 h. For
EEV, supernatants were harvested and centrifuged twice at 3,000 rpm in a
Sorvall RT 6000B to remove cells. Then, supernatants were centrifuged at 22,000
rpm in a Beckman L8-70 M for 80 min to pellet virus. For IMV, cells were
scraped into 10 mM Tris (pH 9.0) and Dounce homogenized. After a low-speed
centrifugation, virus was pelleted through a 36% sucrose cushion. Afterwards,
both the EEV and IMV were purified on a CsCl gradient (layered densities of
1.3, 1.25, and 1.2 g/ml) and centrifuged at 32,000 rpm with slow acceleration for
60 min in a Beckman L8-70 M.
Syncytium formation. Confluent BS-C-1 cell monolayers were infected at an
MOI of 10 for 2 h, washed, and incubated in medium for an additional 10 h as
described previously (47). Cells were washed and treated with fusion buffer
[phosphate-buffered saline with 10 mM 2-(N-morpholino)ethanesulfonic acid
and 10 mM HEPES] at pH 5.5 or 7.4 for 2 min at 37°C. Afterwards, fusion buffer
was replaced by medium, and the cells were incubated at 37°C and then observed
by phase-contrast microscopy.
Determination of virulence in mice. Groups of six female BALB/c 6-week-old
mice were anesthetized and intranasally challenged with 104 to 106 PFU of
vA35, WR, vA35-Res virus, or PBS in 20 	l 10 mM Tris-HCl (pH 9.0). Virus
titers were determined on the day of challenge to confirm virus dose. Individual
mice were weighed every 2 days, and mice were sacrificed if they lost 30% of their
body weight. All animal experiments were carried out in accordance with Na-
tional Institutes of Health guidelines.
RESULTS
vA35 mutant virus forms normal plaques. A35R orthologs
are conserved in all mammalian-tropic poxvirus genomes, ex-
cept the ORF is fragmented in variola virus (13, 55). To assess
the importance of the A35R protein in the virus life cycle, a
recombinant VV was constructed replacing all but four of the
A35R coding nucleotides by the E. coli gpt gene (Fig. 1A).
Recombinant viruses were selected, purified, and screened by
PCR to confirm the absence of the A35R gene (data not
shown). Several virus isolates missing the A35R gene grew
normally on African green monkey normal kidney BS-C-1
cells, forming large wild-type plaques (Fig. 1B). To determine
whether the A35R gene plays a role in VV host range, growth
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of the vA35 mutant was assessed on several cell lines: RK-13
normal rabbit kidney, CV-1 normal African green monkey
kidney; HeLa human cervical adenocarcinoma; human TK;
A549 human lung carcinoma; MRC-5 normal human lung fi-
broblast, and BHK-21 hamster kidney cells. The vA35mutant
grew normally (data not shown) on all cell lines tested, sug-
gesting that A35R is not involved in host range growth of VV
in any of these cell lines.
vA35 mutant virus replicates normally. To evaluate the
kinetics of virus replication, a one-step growth curve was per-
formed. BS-C-1 cells were infected with WR or vA35 at an
MOI of 10 for 2 h, and then inocula were removed. At various
time points postinfection, virus in the medium and associated
with cells were collected, and titers were determined. There
was a 
2-fold difference between the amount of virus pro-
duced by WR- or vA35-infected cells, except at 48 h postin-
fection (hpi) when vA35made 2.4 times as much virus as WR
(Fig. 2). Virus in the supernatant varied by
1.4 fold at all time
points after 8 hpi. Since virus particles begin to be released
after approximately 8 hpi, virus present before that time was
expected to represent input virus. These results indicate that
A35R is not required for normal replication and production of
intracellular or extracellular virus particles.
A35R protein is expressed early. The VV A35R ORF is
predicted to encode a 20-kDa protein. Proteins from infected
cells were analyzed by Western blotting for reactivity with
polyclonal antisera prepared by immunization of rabbits with
synthetic hydrophilic peptides chosen from the predicted
A35R protein sequence. Figure 3A shows that the rabbit poly-
clonal sera recognized a 23-kDa band in proteins expressed in
FIG. 2. Wild-type (WR) or vA35 replication in a one step growth
curve. BS-C-1 cells were infected with wild-type (WR) or vA35 at an
MOI of 10, and supernatants and cells were harvested at designated
time points postinfection. Cell-associated virus and virus in the me-
dium were titrated on separate BS-C-1 monolayers. Representative
data are shown.
FIG. 1. vA35 mutant virus. (A) To construct the vA35 mutant
virus, wild-type (WR) infected cells were transfected with a recombi-
nant PCR product containing A34R and A36R flanking sequences
with the A35R gene replaced by the E. coli gpt gene. The recombinant
vA35 was selected in medium containing mycophenolic acid.
(B) Wild-type and vA35 mutant viruses form similarly sized plaques
on BS-C-1 cell monolayers. Monolayers were stained with crystal violet
40 h postinfection.
FIG. 3. A35R protein expression during poxvirus infection.
(A) Western blot of A35R protein at time points 3, 6, and 18 h
postinfection with wild-type WR (W) or vA35 () mutant virus. The
arrow points to the expressed A35R protein band. (B) A35R protein is
expressed early in infection. Cells were infected with wild-type (WT) or
vA35 mutant virus and pulse labeled with [35S]methionine for 2 h at
the times shown (hours postinfection). Cytosine arabinoside (AraC)
was also added 1 h prior to infection into wells containing each virus
sample to inhibit DNA replication and late gene expression. At the end
of the labeling period, cells were processed for immunoprecipitation
with polyclonal anti-A35R sera. The arrow points to the A35R protein
band expressed.
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wild-type-infected cells but not in cells infected with the
vA35R. In Western blots, the antisera to peptides 55 to 85
and 102 to 111 gave the strongest signals (data not shown) and
are used throughout this paper.
Searching upstream of the predicted A35R translation ATG
start site showed the absence of a late promoter TAAAT
element within 150 bp and the presence of a putative early
promoter element, AAAAAATGAATTAATA, from position
24 to39. This putative early promoter differs from the early
promoter consensus sequence (8) by the presence of two T
residues (underlined) in the A35R promoter region in place of
two A residues present in the consensus. Since the TT dinu-
cleotide is found in this position in known early promoters (8),
it seemed likely that this was a functional early promoter. As
shown in Fig. 3B, the A35R protein could be detected in
wild-type-infected cells by Western blotting from 3 to 18 hpi.
To determine the expression time of the A35R protein, pro-
teins from wild-type- and vA35 mutant virus-infected cells
were metabolically labeled at time intervals after infection.
Figure 3B shows that the A35R protein is expressed in wild-
type virus-infected cells during a 1- to 3-h period after infection
and that no significant expression of A35R occurred between 5
to 7 h postinfection, or 18 to 20 h postinfection (data not
shown). The presence of cytosine arabinoside, a DNA synthe-
sis inhibitor that also blocks VV late gene expression, did not
block the expression of A35R. These data confirm that A35R
is expressed early during the infection cycle in wild-type-in-
fected cells.
Together, these data indicate that while the A35R protein is
expressed early, the A35R protein is stable and present
through later stages of the virus life cycle, albeit at lower
concentrations.
A35R hydrophobic nature. Sequence analysis of the A35R
open reading frame showed that the A35R protein is very
hydrophobic (Fig. 4A). The multiple hydrophobic areas of the
protein suggested that it might be a membrane protein. The
amino terminus contains a stretch of hydrophobic amino acids
suggestive of a signal peptide; however, analysis with SignalP
software (41, 42) did not predict this region to encode a signal
peptide. Analysis by TMpred software (25), however, reported
a significant transmembrane score (556) in the region from
amino acid (aa) 112 to aa 130. Any score over 500 is considered
significant; however, this score was much lower than the scores
for the known A33R and A34R transmembrane regions, which
were near 2000. The A35R protein was predicted to encode
two potential N-linked glycosylation consensus sites at aa 120
and 152.
A35R partitions into the aqueous phase in TX-114 parti-
tioning. The hydrophobic nature of the A35R protein was
assessed in TX-114 partitioning. Integral membrane proteins,
glycophospholipid-linked proteins, and proteins associated
with membranes through acylation all generally partition into
the detergent phase, whereas soluble proteins partition into
the aqueous phase (4, 31, 45). Figure 4B shows a standard
radioimmunoprecipitation of infected cell lysates and immu-
noprecipitations from TX-114 partitioned samples. The A35R
protein reproducibly partitioned into the aqueous phase and
was undetectable in the detergent phase. These data suggest
that A35R is a soluble cytoplasmic protein.
In vitro expression of A35R. The VV strain WR A35R ORF
was cloned into pGEM and pTM1 vectors under control of the
T7 promoter and expressed with an in vitro transcription and
translation system. Proteins were metabolically labeled with
[35S]methionine. Autoradiography showed that vector con-
structs with the A35R ORF inserted after the promoter pro-
duced a protein with an apparent molecular weight (MW) of
23,000 (Fig. 4C). The quantity of protein produced was higher
FIG. 4. Biochemical characterization of A35R protein. (A) The
hydrophobic region predicted to be a transmembrane region by TM-
pred software is shown with a line above and labeled TMpred. (B) Tri-
ton X-114 partitioning. Cells were infected with wild-type WR (W) or
vA35 () mutant virus and then lysed in either radioimmunoprecipi-
tation buffer (Rip) or 2% TX-114 buffer. TX-114 lysates were warmed,
and proteins were separated into aqueous soluble phase (Sol Aq) and
detergent phase (TX-114). All samples were then immunoprecipitated
with anti-A35R sera. The arrow points to the expressed A35R protein
band visible in the Rip sample and in the aqueous phase. (C) Auto-
radiogram of proteins transcribed and translated in vitro in the ab-
sence of microsomal membranes. Protein expression is shown from
two pTM1-derived plasmids containing A35R (A35pTM A1 and A2),
a pGEM-derived plasmid containing the A35R (A35pGEM), and the
luciferase control plasmid. The arrow points to the expressed A35R
protein band. (D) Western blot with polyclonal anti-A35R sera. The
blot shows proteins expressed in vitro from the luciferase control
plasmid (pLucif), the pTM1 derived A35R expressing plasmid (pA35),
the A35R deletion mutant virus-infected cells (vA35), and wild-type
virus-infected cells (vWT). The arrow points to the A35R protein
band.
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in the pTM1 vector due to the presence of the encephalomyo-
carditis leader translational enhancer in this vector. Empty
vector and luciferase controls are also shown and produced
either no protein or a protein of the expected MW of lucif-
erase, respectively. The apparent MW of A35R was slightly
greater than the predicted MW of 20,000. As these proteins
were expressed in the absence of microsomal membranes, only
the peptide backbone of the protein, without any glycosylation,
was produced in this system. In vitro-expressed proteins were
compared to A35R expressed in infected cells in a Western
blot. Figure 4D shows that A35R protein has the same appar-
ent MW whether expressed in an in vitro transcription/trans-
lation system or in infected cells, suggesting that the A35R
protein is not glycosylated or otherwise posttranslationally
modified in vivo in such a way as to significantly alter the MW.
Intracellular localization of A35R. Clues to protein function
can be inferred from the intracellular localization of a protein.
To determine the distribution of A35R, uninfected, wild-type-
infected, and vA35-infected cells were fixed, permeabilized,
and stained with anti-A35R polyclonal sera and fluorescence-
labeled secondary antibody (Fig. 5, right). Hoechst stain was
used to visualize nuclei and virus factories (extranuclear areas
of DNA) (Fig. 5, left). A35R showed a diffuse cytoplasmic
localization in wild-type-infected cells but was often concen-
trated in virus factories. Figure 5 shows WR-infected cells with
five virus factory areas (lower left); A35R protein is shown
concentrated in all five of these locations (lower right). This
staining pattern indicates that A35R specifically localizes to
virus factories where DNA replication, transcription, and early
morphogenesis occur.
vA35 mutant virus undergoes normal morphogenesis and
is infectious. Since the vA35 forms normal plaques, it was
expected that the virus would proceed normally through mor-
phogenesis. To determine whether the A35 mutant virus
formed normal amounts of the various morphogenic forms of
virus, virus particles from wild-type and vA35 mutant infec-
tions were purified by CsCl gradient centrifugation. In the first
experiment, the quantities of wrapped and unwrapped virus
from supernatants were measured by absorbance of 260-nm
light. vA35 released 98% and 103%, respectively, of the
amount of wrapped and unwrapped virus released by wild-type
virus-infected cells. In a second experiment, proteins were met-
abolically labeled with [35S]methionine, and quantities of virus
were measured in duplicate by radioactive counts. vA35
formed from 63 to 74% of the wild-type morphogenic forms
resolved on CsCl gradients (cell-associated unwrapped and
wrapped particles and wrapped virions in the medium). These
data were consistent with the formation of large plaques by the
vA35 mutant and the one-step growth curve (Fig. 2), which
showed that the vA35 produced as much intracellular and ex-
tracellular virus as wild-type-infected cells with similar kinetics.
Formation of wrapped virus particles is required for acid
induced fusion of virus-infected cells (3, 9, 22, 47, 49). To
further assess the effects of deletion of the A35R gene, cells
were infected with wild-type and vA35 and then acid treated
(Fig. 6). Results showed that A35R protein was not required
for polykaryon formation. These data confirm that there was
no significant defect in virus morphogenesis.
To assess the infectivity of vA35 EEV, cells were infected
with similar numbers of WR and A35 EEV particles (mea-
sured by absorbance at 260 nm) and scored for plaque forma-
tion. The vA35 produced 87% of the infectivity of wild-type
virus, indicating that there was little loss of infectivity in the
A35 mutant virions.
Analysis of CsCl-purified virus particles by immunoprecipi-
tation and Western blotting detected A35R protein associated
with intracellular (IMV and IEV) particles; however, A35R
could also be detected in nuclear pellet and cell membrane
fractions, suggesting that the hydrophobic nature of the A35R
protein causes nonspecific association with membranes in the
cytoplasm. In support of this hypothesis, A35R protein was not
detectable in similar numbers of EEV particles (estimated
from absorbance at 260 nm), possibly because EEV sheds its
outermost membrane (the membrane exposed to cytoplasmic
A35R) upon egress from the infected cell. Since the IMV is
contained within the EEV and the EEV is contained within the
IEV, it is difficult to envision a model whereby a protein could
be present in IMV and IEV but not EEV. Further study will be
required to determine whether A35R is specifically packaged
into virions or simply associates nonspecifically with cytoplas-
mic membranes.
vA35mutant virus is attenuated in mice. Since the absence
of the A35R protein had no detectable effect on the virus life
cycle in vitro and A35R orthologs are highly conserved, we
hypothesized that the A35R protein functions in virulence. To
test this, it was first desired to construct a rescue virus, vA35-
Res, from the vA35 virus to show that any phenotype of the
vA35 virus was due to loss of the A35R, rather than a mu-
tation in another locus. Therefore, a recombinant virus was
engineered from the vA35 in which the A35R gene was
FIG. 5. A35R intracellular localization. BS-C-1 cells were infected
with wild-type WR or vA35 at an MOI of 2.5 for 10 h and then fixed,
permeabilized, and labeled with anti A35R antisera at a 1:5,000 dilu-
tion. Secondary antibody was conjugated to the immunofluorescent
dye Alexa 568, and DNA was stained with Hoechst. (Left) Hoechst
staining of nuclei and cytoplasmic virus factories (arrows); (right)
A35R staining in the same cells.
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returned to its original locus. It was unlikely that the vA35
phenotype was due to disruption of the neighboring A34R or
A36R gene expression because only the A35R-coding region
was removed in the vA35 and the mutant virus formed large
plaques. Disruption of A34R or A36R expression causes a
small plaque phenotype (11, 37, 60), and the vA35 forms
normal plaques.
To determine virulence in mice, groups of 5-week-old fe-
male BALB/c mice weighing between 14 and 17 g apiece (six
mice per group) were anesthetized and intranasally challenged
with 104 to 106 PFU of purified wild-type WR, vA35, vA35-
Res, or PBS in 20 	l. Virus titers were determined on the day
of challenge to confirm virus dose. Mice were weighed to
monitor health and sacrificed if they lost 30% of their original
body weight. Figure 7 shows that over the course of the exper-
iment, mice challenged with PBS or vA35 gained between 10
and 11% in body weight, whereas mice challenged with 104
PFU of the vA35-Res or VV strain WR lost, on average, 16%
and 26% of their body weight, respectively, by day 10. Two
WR-challenged mice (and no others) died between day 9 and
11. This experiment was repeated, and attenuation of the
vA35 was also seen at higher challenge doses. At 105 PFU,
one mouse challenged with vA35 died, compared to four with
WR and six with vA35Res. When challenged with 106 PFU, all
mice died, but survival was increased by 1 to 2 days in the
vA35. With WR, two mice died on day 6, and four died on
day 7. When challenged with A35Res, all six mice died on day
6; but with vA35, four mice died on day 7 and two survived
until day 8. Together, these data clearly show that the A35R
protein is important for virulence in mice.
DISCUSSION
This paper presents the initial characterization of the A35R
protein in VV. A35R is expressed early during infection, has an
apparent MW of 23,000 in sodium dodecyl sulfate-polyacryl-
FIG. 6. Acid-induced fusion of infected cells. Cells were infected with the wild type or vA35 for 12 h, incubated for 2 min in buffer at pH 5.5,
returned to growth medium, and photographed after 3 h.
FIG. 7. vA35 challenge in mice. Groups of 5-week-old mice (six mice per group) were intranasally challenged with 104 PFU of WR, vA35,
vA35-Res, or PBS. Mice were weighed every 2 days and sacrificed if they lost 30% of their body weight (shown on righthand y axis). In a second
experiment, mice were challenged with 105 and 106 PFU and weighed as before. Crosses on the 104 and 105 PFU graphs indicate the numbers of
dead animals in the adjacent group. In the 106 PFU challenge dose, all animals died by day 8.
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amide gel electrophoresis, and is not glycosylated or secreted.
It does not behave as an integral membrane protein in TX-114
analysis and concentrates intracellularly to virus factories. De-
letion of the A35R gene does not significantly hinder virus
morphogenesis, infectivity, or spread in vitro but has a signif-
icant impact on virulence in the mouse intranasal challenge
model.
The A35R gene is predicted to encode a 176-aa protein in
VV Copenhagen (21), modified vaccinia Ankara (1), and Tian
Tan strains (GenBank AF095689). The VV-A35R orthologs
are conserved in all poxviruses with a mammalian host range,
ranging in size from 176 to 192 aa in all sequenced viruses,
except for a large ortholog of 233 aa in molluscum contagio-
sum virus (55). However, the gene is fragmented into 60-aa
and 50-aa ORFs in variola virus sequences (India, Bangladesh,
and Garcia) (35, 50–52). While this fragmentation potentially
preserves 63% of the coding sequence, experimental evidence
will be required to determine whether these proteins are ex-
pressed or might be functional in variola virus. Its conservation
in molluscum contagiosum virus, a pathogen restricted to hu-
mans, suggests that the larger molluscum contagiosum virus
ortholog may have a function in infecting and surviving in the
human host. It is possible that the smaller orthopox A35R
protein may not function in human hosts and thus was lost
from variola or that other virulence mechanisms in variola
made A35R unnecessary.
The wide conservation of A35R orthologs suggests an im-
portant role for this protein in some aspect of the virus life
cycle. Our characterization here indicates that the A35R is not
required in vitro for replication and spread of the virus but that
the A35R has a function in virulence. Since the A35R is not
secreted, it must execute its function intracellularly. A wide
variety of possibilities exist. A35R could block some stage of
antigen processing or presentation in infected cells or interfere
with regulation of apoptosis. In addition, the A35R function
may be required for growth in certain cell types, e.g., macro-
phage, in vivo. The fact that the A35R protein has little ho-
mology to non-poxvirus proteins suggests that the A35R pro-
tein participates in a novel virulence mechanism.
Two lines of evidence suggest that the A35R may function in
gene regulation; it localizes to factories where viral DNA is
located and it was shown to be a constitutive transcriptional
activator in a large-scale yeast two-hybrid study (36). Most
A35R orthologs are acidic, ranging in pI between 4.4 and 4.6 in
the genus Orthopoxvirus. The acidity suggests that these pro-
teins may act as an acid blob in activation of transcription.
There is one notable exception to the acid nature of A35R
orthologs. MCV contains an A35R ortholog predicted to en-
code a 233-aa protein with a pI of 8.5. However, the MCV
protein has only one fewer acidic residue (20) than the or-
thopox proteins, so depending on the protein tertiary folding,
it could still potentially form an acid blob domain. In VV, it is
clear that there is no major defect in gene expression in the
absence of A35R, because all of the large number of proteins
required for virion formation and spread (Fig. 1, 2, and 6) are
apparently expressed normally. Furthermore, background pro-
tein band patterns were apparently not different between the
two viruses from early to late infection times (Fig. 3 and 4).
The possibility remains that A35R has a role in some gene-
specific transcription activity, something that has not been
demonstrated in poxviruses. The early temporal expression of
the A35R is consistent with a function either in host interac-
tions or in transcription during infection.
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